

DESCRIPTION

Species Reactivity	Canine
Specificity	Detects canine CCL5/RANTES in direct ELISAs. In Western blots, no cross-reactivity with recombinant CCL5/RANTES from cat, cotton rat, mouse, or human is observed. No cross-reactivity with recombinant mouse CCL7/MARC, rmCCL17/TARC, recombinant human (rh)&n
Source	Monoclonal Mouse IgG ₁ Clone # 676106
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant canine CCL5/RANTES Ser24-Ser91 Accession # Q8HYS0
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunocytochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa β-chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1-3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature canine CCL5 shares 74%-84% amino acid sequence identity with cotton rat, feline, human, mouse, and rat CCL5. CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (5, 6). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (7). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (8). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (9). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5's interaction with the chemokine CXCL4/PF4 (10-12). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (13-15). CCL5 is up-regulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (16).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.